Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24023501 | 0.98 | POLB (1.00) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL13293705 | 0.98 | POLB (1.00) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL30596563 | 0.98 | POLB (1.00) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL24023500 | 0.98 | POLB (1.00) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL5794134 | 0.93 | POLB (0.83) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL10897828 | 0.85 | CXCR4 (0.76) | POLBSMN1; SMN2SIGMAR1HRH3 | |
| SCHEMBL2094810 | 0.85 | POLB (0.71) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL980493 | 0.85 | SMN1; SMN2 (0.71) | POLBSMN1; SMN2SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL24023627 | 0.85 | SIGMAR1 (1.00) | POLBSMN1; SMN2SIGMAR1HTTCYP2D6 | |
| SCHEMBL5618352 | 0.85 | SMN1; SMN2 (0.71) | POLBSMN1; SMN2SIGMAR1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-104169258-B | novel heterocyclic carboxamides as modulators of kinase activity | 默克专利有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-6821964-B2 | FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION | PFIZER INC | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | POLB 4759/4885SMN1; SMN2 2485/4885SIGMAR1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.